Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) were down 3.4% during trading on Monday . The company traded as low as $33.21 and last traded at $33.70, with a volume of 1,977,749 shares. The stock had previously closed at $34.87.

A number of analysts have commented on AERI shares. HC Wainwright started coverage on Aerie Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $66.00 target price on the stock. Raymond James Financial Inc. started coverage on Aerie Pharmaceuticals in a research report on Tuesday, September 13th. They set an “outperform” rating and a $48.00 target price on the stock. Brean Capital reiterated a “buy” rating and set a $48.00 target price on shares of Aerie Pharmaceuticals in a research report on Wednesday, September 7th. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $45.00 target price on shares of Aerie Pharmaceuticals in a research report on Tuesday, August 23rd. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Aerie Pharmaceuticals has a consensus rating of “Buy” and an average target price of $49.40.

The company’s 50-day moving average is $20.94 and its 200-day moving average is $17.12. The firm’s market capitalization is $1.04 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.02. Equities research analysts predict that Aerie Pharmaceuticals Inc. will post ($2.77) EPS for the current fiscal year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. purchased 250,000 shares of the firm’s stock in a transaction on Friday, July 22nd. The stock was purchased at an average cost of $17.50 per share, with a total value of $4,375,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 8.77% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares during the last quarter. ProShare Advisors LLC raised its stake in Aerie Pharmaceuticals by 3.0% in the second quarter. ProShare Advisors LLC now owns 22,695 shares of the company’s stock valued at $399,000 after buying an additional 669 shares in the last quarter. Tocqueville Asset Management L.P. raised its stake in Aerie Pharmaceuticals by 1.7% in the second quarter. Tocqueville Asset Management L.P. now owns 42,300 shares of the company’s stock valued at $744,000 after buying an additional 725 shares in the last quarter. Geode Capital Management LLC raised its stake in Aerie Pharmaceuticals by 0.6% in the first quarter. Geode Capital Management LLC now owns 161,319 shares of the company’s stock valued at $1,961,000 after buying an additional 925 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its stake in Aerie Pharmaceuticals by 4.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 24,578 shares of the company’s stock valued at $433,000 after buying an additional 1,019 shares in the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.